3 Fantastic Growth Stocks to Buy in August | The Motley Fool (2024)

These stocks should keep up their winning ways.

The recent stock market sell-off appears to have fizzled out and now could be a great time for long-term investors to put some of their cash to work.

Three Motley Fool contributors think they've found fantastic growth stocks to buy in August. Here's why they picked Eli Lilly (LLY -0.03%), Novo Nordisk (NVO 0.27%), and Vertex Pharmaceuticals (VRTX 2.24%).

A behemoth that could double in size

David Jagielski (Eli Lilly): Growth investors might be tempted to look for small-cap stocks in the hopes of maximizing long-run returns, but one of the best growth stocks in healthcare is also the largest: Eli Lilly. At a market cap of around $800 billion, it's likely only a matter of time before it becomes the first healthcare stock to reach a $1 trillion valuation. I think the stock could go far higher than that, potentially doubling within the next five years.

Lilly's latest quarterly results highlighted why this is a fantastic growth stock to buy. It has been a little over two years since the U.S. Food and Drug Administration (FDA) approved diabetes medication Mounjaro. The drug's sales topped $3.1 billion in Lilly's most recent quarter, which ended on June 30. Regulators approved Zepbound (which contains the same active ingredient as Mounjaro) for weight loss in November of last year. It's bound to be another huge drug for Eli Lilly, already raking in $1.2 billion in revenue last quarter.

The only thing stopping Eli Lilly these days is its constrained capacity. There's simply too much demand for the company's diabetes and weight loss medications. Lilly is working feverishly to expand capacity so that it can sell more of these highly coveted products. And investors also shouldn't forget the company's recently approved early Alzheimer's treatment, Kisunla, which is likely to be yet another blockbuster drug.

Eli Lilly is not only a safe healthcare stock to invest in but it's a growth beast, with loads of potential in the long run, and the business is only going to get far more valuable in the years ahead.

A pharmaceutical giant defying gravity

Prosper Junior Bakiny (Novo Nordisk): Investors looking for a stock firing on all cylinders need look no further than Novo Nordisk. This leading drugmaker has been flying over the past five years, delivering strong financial results, making steady clinical progress, and performing better than most of its similarly sized peers.

Novo Nordisk likely won't slow down significantly anytime soon. The company's two main growth drivers, weight loss medicine Wegovy and diabetes therapy Ozempic, are still going strong. These have become famous brands, a feat more common in the tech industry than in pharmaceuticals. And while Novo Nordisk's success is attracting scores of competitors, the company is likely to remain near the top of the fast-growing anti-obesity market.

Novo Nordisk boasts several highly promising candidates in this area. Perhaps one worry some investors have is that Eli Lilly is too reliant on its diabetes and obesity portfolio. People probably can't name drugs in other fields that significantly contribute to its top-line growth. That's because there aren't any. However, Novo Nordisk is looking to diversify its lineup. Its pipeline features potential medicines for Parkinson's, hemophilia, sickle cell disease, thalassemia, and other conditions.

Even if other companies eat up some of its market share in its core areas, Novo Nordisk should eventually successfully launch at least a few blockbusters elsewhere to compensate. Don't underestimate the drugmaker's innovative potential. It is largely responsible for its current success and will continue driving the stock to greater heights over the long run. Novo Nordisk is an excellent stock to buy this month, or any month, for that matter.

Growth, growth, and more growth

Keith Speights (Vertex Pharmaceuticals): Growth hasn't been a problem whatsoever for Vertex Pharmaceuticals in recent years. The company enjoys a monopoly in treating the underlying cause of the rare genetic disease cystic fibrosis (CF). Its CF sales could accelerate if Vertex's vanzacaftor triple-drug combo receives FDA approval, which could be on the way by early 2025.

Vertex is poised to generate further growth outside of CF. The launch of Casgevy as a one-time treatment for rare blood disorders sickle cell disease and transfusion-dependent beta-thalassemia is still ramping up. Casgevy is the first CRISPR gene-editing therapy to receive FDA approval.

More growth (and I'd go as far as to say much more growth) could be coming soon. Vertex awaits FDA approval of suzetrigine for the relief of acute pain. As a non-opioid, I think the drug should have tremendous commercial potential.

Vertex is evaluating inaxaplin in a late-stage clinical study targeting APOL1-mediated kidney disease (AMKD). There are currently no approved therapies for treating the underlying cause of AMKD. The company's recent acquisition of Alpine added povetacicept to its pipeline. The experimental drug is another late-stage candidate targeting kidney disorders.

Perhaps best of all, Vertex's valuation doesn't reflect its tremendous growth prospects. The stock's price-to-earnings-to-growth (PEG) ratio is a low 0.67. Any stock with a PEG ratio below 1.0 is considered to be attractively valued.

David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

3 Fantastic Growth Stocks to Buy in August | The Motley Fool (2024)

FAQs

3 Fantastic Growth Stocks to Buy in August | The Motley Fool? ›

Three Motley Fool contributors think they've found fantastic growth stocks to buy in August. Here's why they picked Eli Lilly (LLY 0.80%), Novo Nordisk (NVO 0.22%), and Vertex Pharmaceuticals (VRTX 0.04%).

What are 3 growth stocks to buy now? ›

Best-performing growth stocks
TickerCompanyPerformance (Year)
NUNu Holdings Ltd117.52%
EATBrinker International, Inc.117.24%
HIMSHims & Hers Health Inc115.42%
COINCoinbase Global Inc114.46%
17 more rows
Sep 3, 2024

What is Motley Fool's all in buy? ›

We regularly see similar ads from the Motley Fool about “all in” buy alerts, sometimes also called “double down” or “five star” buys, and they're generally just the type of steady teaser pitch that they can send out all year, over and over with no updates, to recruit subscribers for their flagship Motley Fool Stock ...

What stocks will skyrocket in 2024? ›

Best S&P 500 stocks as of September 2024
Company and ticker symbolPerformance in 2024
Howmet Aerospace (HWM)78.6%
General Electric (GE)71.2%
Targa Resources (TRGP)69.1%
Constellation Energy (CEG)68.3%
6 more rows

What stock will grow fast? ›

10 Best Growth Stocks to Buy for 2024
StockImplied upside*
Nvidia Corp. (NVDA)12.3%
Alphabet Inc. (GOOG, GOOGL)32.9%
Broadcom Inc. (AVGO)13.9%
JPMorgan Chase & Co. (JPM)6.2%
6 more rows
Aug 23, 2024

Which stock has huge growth potential? ›

high growth potential stocks
S.No.NameCMP Rs.
1.Guj. Toolroom12.38
2.Swadeshi Polytex106.60
3.Maha Rashtra Apx166.75
4.Press. Senstive6.17
22 more rows

Which stocks that double every 3 years? ›

Stock Doubling every 3 years
S.No.NameMar Cap 3yrs back Cr.
1.P. H. Capital8.60
2.Jyoti Resins210.06
3.HB Stockholdings11.85
4.Systematix Corp.193.41
22 more rows

What are Motley Fool's 3 double down stocks? ›

See 3 “Double Down” stocks »

The Motley Fool has positions in and recommends Amazon, Chewy, and Meta Platforms. The Motley Fool has a disclosure policy.

What is the Motley Fool's AI stock pick? ›

The Motley Fool has positions in and recommends Alphabet, Amazon, Datadog, Microsoft, MongoDB, Nvidia, Palantir Technologies, ServiceNow, and Snowflake.

What is the golden star in stocks? ›

The 'Golden Star' signal differs from the 'Golden Cross' by adding more conditions for the signal to appear. For instance, the moving averages have to be selected based on the time frame that was selected. In addition, it has to cross the price line at a given pattern as shown below.

Which stock will double in 6 months? ›

6 months double
S.No.NameCMP Rs.
1.Sri Adhik. Bros.677.45
2.Ujaas Energy544.25
3.Eraaya Lifespace1469.60
4.Marsons201.60
22 more rows

What is the best performing stock of all time? ›

Nvidia Corp.

Nvidia shares have gained 322,185% overall in the past 30 years, a 37.2% average annual return, making it the best-performing S&P 500 stock of the past three decades.

What is the most profitable stock to buy right now? ›

9 Best Stocks To Buy Now
Company (Ticker)Forward P/E Ratio
TopBuild Corp. (BLD)18.2
Citigroup, Inc. (C)50.8
The Kraft Heinz Company (KHC)8.7
Fidelity National Information Services, Inc. (FIS)18.4
5 more rows
Aug 29, 2024

Which stock is always increasing? ›

consistently growing stocks
S.No.NameProfit Var 5Yrs %
1.Ksolves India192.45
2.Waaree Renewab.144.87
3.Lloyds Metals129.25
4.Crestchem71.06
22 more rows

What stock went up 1000 percent in a day? ›

Even so, the gains posted by Ambrx Biopharma (AMAM) in Friday's session are unusual and particularly eye-catching. The stock soared to the tune of a hardly believable 1007% after the company announced pleasing results from the mid-stage testing of its breast cancer drug ARX788.

What are the top 3 most active stocks today? ›

Stocks
SymbolPriceChange
NVDA NVIDIA Corporation116.91 +8.81 (+8.15%)+8.81
TSLA Tesla, Inc.228.13 +1.96 (+0.87%)+1.96
HPE Hewlett Packard Enterprise Company16.40 +0.30 (+1.86%)+0.30
PLTR Palantir Technologies Inc.34.85 +0.09 (+0.26%)+0.09
21 more rows

What are the three best stocks to buy? ›

Sign up for Kiplinger's Free E-Newsletters
Company (ticker)Analysts' consensus recommendation scoreAnalysts' consensus recommendation
UnitedHealth Group (UNH)1.27Strong Buy
Emerson Electric (EMR)1.30Strong Buy
Microsoft (MSFT)1.32Strong Buy
Nvidia (NVDA)1.32Strong Buy
19 more rows

Which stock is best to buy in grow? ›

Sectors
CompanyCMP (Rs)Profit CAGR (5 yrs, %)
ICICI BANK1,237.959.8%
ADANI POWER635.5NM
TATA CONSUMER1,188.222.4%
PNB109.7NM
21 more rows

Which stock will go up in 3 months? ›

Highest returns in three months
S.No.Name3mth return %
1.Lotus Chocolate305.99
2.Pondy Oxides231.53
3.Balu Forge185.50
4.Refex Industries156.55
22 more rows

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Manual Maggio

Last Updated:

Views: 6017

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Manual Maggio

Birthday: 1998-01-20

Address: 359 Kelvin Stream, Lake Eldonview, MT 33517-1242

Phone: +577037762465

Job: Product Hospitality Supervisor

Hobby: Gardening, Web surfing, Video gaming, Amateur radio, Flag Football, Reading, Table tennis

Introduction: My name is Manual Maggio, I am a thankful, tender, adventurous, delightful, fantastic, proud, graceful person who loves writing and wants to share my knowledge and understanding with you.